Your February Newsletter from Glaucoma Research Foundation.
| | | Dear Tushar:
The only current treatment for glaucoma is to lower intraocular pressure (IOP), which can be achieved with eyedrops, laser, or incisional surgery. Eye drops are the most common treatment modality and, over time, patients may need to take multiple types of eye drops in order to stop progression of a disease that typically has no symptoms.
These drops lower IOP by reducing fluid formation or encouraging better drainage of fluid from the eye via one or both of two pathways: the trabecular meshwork/Schlemm's canal (TM/SC) and the uveoscleral pathway.
Currently in the United States there are 5 families of eyedrops that are used to lower IOP. In the near future, new compounds that reduce IOP may become available and this article provides an overview of glaucoma medications "in the pipeline." These new compounds are often combined with a prostaglandin compound (a currently available class of medication) in the same bottle, or the compound itself has a prostaglandin "backbone," such that IOP is lowered via multiple mechanisms while maintaining a convenient, once daily dosing.
| | Annual Gala Raises Funds for Glaucoma Research Earlier this month, the Glaucoma 360 Annual Gala at San Francisco's historic Palace Hotel honored leaders in glaucoma research innovation and philanthropy. Glaucoma Research Foundation's 2017 Visionary Award was presented to Janette Márquez, a talented and accomplished opera singer who is blind from congenital glaucoma. Watch her inspiring comments and performance in this video: | | |
| | |
| |
No comments:
Post a Comment